Lucid Diligence Brief: Eli Lilly Pipeline Rationalization
Lucid Diligence Brief: Eli Lilly Pipeline Rationalization Professional…
Lucid Diligence Brief: Formation Bio licenses miR-124 activator FHND5032 from CTFH
Lucid Diligence Brief: Formation Bio licenses miR-124 activator FHND5032 from…
Lucid Diligence Brief: GSK to acquire RAPT Therapeutics
Lucid Diligence Brief: GSK to acquire RAPT Therapeutics Professional audiences…
Lucid Diligence Brief: Caldera Therapeutics launches with $112.5 million in IBD
Lucid Diligence Brief: Caldera Therapeutics launches with $112.5 million in……
Lucid Diligence Brief: Mirador Therapeutics $250 million Series B in immuno-fibrotic disease space
Lucid Diligence Brief: Mirador Therapeutics $250 million Series B in…
Respiratory Today—January 9, 2026
This respiratory update spotlights reflects strong momentum across respiratory…
Lucid Diligence Brief: Lilly to acquire Ventyx Biosciences
Lucid Diligence Brief: Lilly to acquire Ventyx Biosciences Professional…
Lucid Diligence Brief: Relation and Novartis atopic disease discovery alliance
Lucid Diligence Brief: Relation and Novartis atopic disease discovery alliance…
Lucid Diligence Brief: Dayra Therapeutics, Versant Ventures and Biogen collaboration
Lucid Diligence Brief: Dayra Therapeutics, Versant Ventures and Biogen…
Lucid Diligence Brief: Accipiter Bio $12.7M Seed Funding
Lucid Diligence Brief: Accipiter Bio $12.7M Seed Funding Professional audiences…
Lucid Diligence Brief: Electra Therapeutics $183M Series C
Lucid Diligence Brief: Electra Therapeutics $183M Series C Professional…
Lucid Diligence Brief: EVOQ x Sanofi collaboration
Lucid Diligence Brief: EVOQ x Sanofi collaboration Professional audiences only.…